Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | AR | P10275 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PPM1D | O15297 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14157151 | 0.80 | MAPT (0.53) | KDM4EARLMNACYP19A1RAB9A | |
| SCHEMBL18171968 | 0.80 | GFER (0.58) | KDM4ELMNACYP19A1RAB9AALDH1A1 | |
| SCHEMBL2623993 | 0.79 | RAB9A (0.49) | KDM4EARLMNACYP19A1RAB9A | |
| SCHEMBL1954255 | 0.79 | KDM4E (0.53) | KDM4EARLMNACYP19A1RAB9A | |
| SCHEMBL20875121 | 0.79 | KDM4E (0.59) | KDM4EARLMNACYP19A1RAB9A | |
| SCHEMBL7532072 | 0.78 | KDM4E (0.73) | KDM4EARLMNACYP19A1RAB9A | |
| SCHEMBL2092693 | 0.76 | KDM4E (0.56) | KDM4EARLMNACYP19A1RAB9A | |
| SCHEMBL2092690 | 0.76 | KDM4E (0.56) | KDM4EARLMNACYP19A1RAB9A | |
| SCHEMBL2155406 | 0.76 | CYP19A1 (0.40) | KDM4EARLMNACYP19A1RAB9A | |
| SCHEMBL1180096 | 0.76 | MAPT (0.59) | KDM4ELMNACYP19A1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779018-B2 | Heterocyclic compound and arthropod pest control composition containing same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-11779018-B2 | Heterocyclic compound and arthropod pest control composition containing same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| EP-3778583-A1 | HETEROCYCLIC COMPOUND AND ARTHROPOD PEST CONTROL COMPOSITION CONTAINING SAME | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-20210030003-A1 | HETEROCYCLIC COMPOUND AND ARTHROPOD PEST CONTROL COMPOSITION CONTAINING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-02-04 | — | — | US | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| CN-102015686-A | Novel heterocyclic compounds and uses therof | NOVARTIS AG | 2011-04-13 | — | — | CN | disclosed |
| EP-2274300-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030003-A1 | HETEROCYCLIC COMPOUND AND ARTHROPOD PEST CONTROL COMPOSITION CONTAINING SAME | C5, PRXL2A, NOX3 | KDM4E 869/4885AR 491/4885LMNA 2635/4885 |
| US-11779018-B2 | Heterocyclic compound and arthropod pest control composition containing same | C5, PRXL2A, NOX3 | KDM4E 869/4885AR 491/4885LMNA 2635/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | KDM4E 3041/4885AR 3762/4885LMNA 2861/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | KDM4E 2526/4885AR 3602/4885LMNA 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.